Existing Lilly Drug in Two Month Trial

President Trump advocated for and promoted two drugs for COVID 19 that were already on the market, but used for different ailments.  While America, and indeed the World, cannot worry too much about new drug proposals that do not have a proven record of safe side effects, it is helpful to look at an existing market's customers to see how safe drugs turn out to be.

The pharmaceutical company, Eli Lilly & Co. (LLY), believes it owns a third, already marketed drug, that can have a positive effect against COVID 19, even though it is usually used against rheumatoid arthritis.  The medicine, called OLUMIANT (otherwise known as baricitinib), will be evaluated in a study to measure efficacy that, unfortunately, is expected to conclude in about two months.

Paul Wharton

Special thanks to Eli Lilly & Co. (LLY) for inventing the fuel of my mind